In issue 1540 on nonopioid drugs for pain (Med Lett Drugs Ther 2018; 60:24), we said that nonacetylated salicylates such as diflunisal and salsalate do not interfere with platelet aggregation. That is not entirely true for diflunisal. Although low doses (250 mg twice daily) of diflunisal have no effect on platelets and the usual dosage of 500 mg twice daily has a minimal effect that is not likely to have clinical signifi cance, a dosage of 1000 mg twice daily, which is larger than the recommended maximum dosage, may transiently inhibit platelet function (D Green et al. Effects of diflunisal on platelet function and fecal blood loss. Pharmacotherapy 1983; 3(2pt2):65S).